Evidence map›Paper›PMID 42637959›Full record

ArticleNature biotechnology2026

Adaptive model-guided protein evolution with sparse data optimizes compact eukaryotic genome editors.

Shijie Wan, Jackson Gold, Pranay Vure, Casey S Mogilevsky, Ananya Talikoti, Tianrong Chen, Aman Gupta, Trisha Biswas, Zheng You, Vir Acharya and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shijie WanDepartment of Chemical and Biomolecular Engineering, University of Pennsylvania, Philadelphia, PA, USA.
Jackson GoldCenter for Precision Engineering for Health, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0009-0001-7206-0710
Pranay VureCenter for Precision Engineering for Health, University of Pennsylvania, Philadelphia, PA, USA.
Casey S MogilevskyCenter for Precision Engineering for Health, University of Pennsylvania, Philadelphia, PA, USA.
Ananya TalikotiCardiovascular Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Tianrong ChenCenter for Precision Engineering for Health, University of Pennsylvania, Philadelphia, PA, USA.
Aman GuptaCenter for Precision Engineering for Health, University of Pennsylvania, Philadelphia, PA, USA.
Trisha BiswasDepartment of Chemical and Biomolecular Engineering, University of Pennsylvania, Philadelphia, PA, USA.
Zheng YouDepartment of Chemical and Biomolecular Engineering, Rice University, Houston, TX, USA.
Vir AcharyaCenter for Precision Engineering for Health, University of Pennsylvania, Philadelphia, PA, USA.
Pranam ChatterjeeCenter for Precision Engineering for Health, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-3957-8478
Xiao WangCardiovascular Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. xiao8@pennmedicine.upenn.edu.ORCID http://orcid.org/0000-0001-7502-8292
Xue GaoDepartment of Chemical and Biomolecular Engineering, University of Pennsylvania, Philadelphia, PA, USA. xuegao@seas.upenn.edu.ORCID http://orcid.org/0000-0003-3213-9704

Funding

Develop High-Precision and Multiplex Base Editing Approaches for Therapeutic ApplicationsR01HL157714 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI GAO, XUE · 2021 to 2024
$2.0M
Chemically inducible split base editors for precise and controllable in vivo genome editingR01HL173243 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI Xue Gao, Zheng Sun · 2025 to 2026
$1.3M
NHLBI NIH HHS R01 HL157714NHLBI NIH HHS R01 HL173243
6 · The paper itself

Abstract

Efficient protein engineering is constrained by vast sequence space and limited experimental throughput, particularly for protein families that lack large mutational datasets. Here we combine Fanzor2 (Fz2) ortholog discovery, ωRNA scaffold engineering and EvoMax, a model-guided prioritization strategy for sparse-data engineering of compact eukaryotic Fz2 nucleases. EvoMax integrates iterative experimental profiling with Gaussian process regression, protein language models and inverse folding to navigate complex sequence-to-fitness landscapes. Applied to eukaryotic Fz2 nucleases, this strategy yielded a high-performance variant, FanzMAX v3-hLa, achieving up to 97% editing efficiency at the best-performing endogenous locus and a mean editing efficiency of ~33% across 19 endogenous loci, outperforming the established compact genome editors enNlovFz2 and enCnCas12f1 by more than 2.6-fold. In vivo editing of hPCSK9 in humanized mice supported the translational potential of optimized Fz2 editors. Together, these results establish EvoMax as an integrated strategy for engineering compact eukaryotic Fz2 genome editors and identify FanzMAX v3-hLa as a high-efficiency programmable nuclease for mammalian genome editing.

Identifiers

PMID42637959

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.